Compare Inovio Pharmaceuticals Inc (INO) vs Ulta Beauty Inc (ULTA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Ulta Beauty Inc — how do they compare? Inovio Pharmaceuticals Inc trades at $1.09 (market cap $89.27M), while Ulta Beauty Inc trades at $492.85 (market cap $20.98B). The key difference: Ulta Beauty Inc is far larger — about 235× Inovio Pharmaceuticals Inc's market cap, and Ulta Beauty Inc is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| INO | ULTA | |
|---|---|---|
Market Cap | $89.27M | $20.98B |
Sector | Health | Consumer Cyclical |
52-Week High | $2.87 | $706.82 |
52-Week Low | $1.05 | $450.75 |
Enterprise Value | $60.28M | $23.06B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.
Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.
ULTA Beauty trades at $488.01, up 1.76% with a bullish technical signal despite mixed moving averages. The company maintains strong profitability with 39.33% gross margins and 47.45% ROE, though revenue growth has slowed to 0.9% in 2025. Recent leadership appointments and international expansion initiatives signal strategic positioning for future growth.
ULTA presents a compelling value opportunity with a 17.97 P/E ratio below historical averages, supported by 56.5% analyst buy ratings and a $618.29 consensus target. However, margin compression risks and competitive pressures require monitoring as the company navigates evolving consumer trends and expansion challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Ulta Beauty Inc
With more than 1,300 stores and a partnership with Target, Ulta Beauty is the largest specialized beauty retailer in the U.S. The firm offers makeup (43% of 2021 sales), fragrances, skin care, and hair care products (20% of 2021 sales), and bath and body items. Ulta offers private-label products and merchandise from more than 500 vendors. It also offers salon services, including hair, makeup, skin, and brow services, in all stores. Most Ulta stores are approximately 10,000 square feet and are in suburban strip centers. Ulta was founded in 1990 and is based in Bolingbrook, Illinois.
Read more on ULTA →
